Ask AI
ProCE Banner Activity

Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction

Slideset

Expert-curated slides on the latest advances in lipid management and atherosclerotic cardiovascular disease risk reduction, including the emerging role of lipoprotein(a), data on novel lipid-lowering therapies, and strategies for individualizing care for patients with hyperlipidemia.

Released: March 25, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

This educational activity is intended for cardiology physicians, nurse practitioners, and physician associates who care for patients with ASCVD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize Lp(a) as an alternative biomarker of ASCVD risk and of residual risk when taking LDL-C into account

  • Plan individualized, guideline-recommended lipid-lowering treatment strategies using nonstatin or combination therapies to improve patient outcomes, as measured by Lp(a)

  • Implement guideline-directed ASCVD care that addresses gaps in patient-centered approaches and avoids clinical inertia

Disclosure

Primary Author

Ty J. Gluckman, MD, MHA, has no relevant financial relationships to disclose.

Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert: consultant/advisor/speaker: Amarin, Amgen, Bayer, Esperion, Idorsia, iRhythm, Merck, Novartis, Novo Nordisk, Pfizer; researcher: Johnson & Johnson/Janssen, Kardia AliveCor.

Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC: consultant/advisor/speaker: Arrowhead, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Lifesciences, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer.

Pam R. Taub, MD, FACC, FASPC: consultant/advisor/speaker: Amgen, Amarin, Bayer, Boehringer Ingelheim, Edwards Lifesciences, Esperion, Jazz, Lexicon, Lilly, Medtronic, Novartis, Novo Nordisk, Roche; researcher: AstraZeneca, CSL Behring, Dexcom, Merck, New Amsterdam.